Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D
02 June 2017 - 6:01AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, today announced the
appointment of John J. Orloff, M.D. to its board of directors,
effective as of July 1, 2017.
Dr. Orloff will resign as Novelion’s Executive
Vice President and Head of Research and Development. A search for
his replacement as Head of R&D is under way.
With Novelion’s commitment to becoming a leader
in rare diseases, Dr. Orloff will continue to provide guidance to
the management team regarding the company’s scientific strategy and
clinical program development, and will assume a significant role in
the oversight of the company as a member of its Board of
Directors.
Jason Aryeh, chairman of the board of directors,
said, "As Novelion strives to achieve its goal of becoming a
leading rare disease company, we welcome Dr. Orloff’s continued
contribution and will rely on his expertise in his new role as a
board member. During his tenure at Novelion, Dr. Orloff has
established a scientific platform for Novelion that positions the
Company for growth in the near- and long-term. His guidance will
continue to be invaluable as Novelion seeks to execute against
multiple development opportunities.”
About Novelion Therapeutics Novelion
Therapeutics is a biopharmaceutical company dedicated to developing
new standards of care for individuals living with rare diseases.
Novelion has a diversified commercial portfolio through its
indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes
MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate
for the potential treatment of inherited retinal disease caused by
underlying mutations in RPE65 or LRAT genes. The company seeks to
advance its portfolio of rare disease therapies by investing in
science and clinical development.
Investors and others should note that we
communicate with our investors and the public using our company
website www.novelion.com, including, but not limited to, company
disclosures, investor presentations and FAQs, SEC filings, press
releases, public conference calls transcripts and webcast
transcripts. The information that we post on these websites could
be deemed to be material information. As a result, we encourage
investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2024 to May 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From May 2023 to May 2024